comprehensive -WSS

comprehensive

author：leisure time 2025-08-23 03:41:07 - browse：696

UnitedHealth Group’s Optum subsidiary saw a lower operating margin in the second quarter due to more seniors getting care, a spike in demand for behavioral health services, and an influx of members with higher health needs.

“Those three elements, the senior trend piece, the behavioral piece, and then the effects of the strong growth is really what explains what’s going on,” UnitedHealth Group CEO Andrew Witty said on the company’s earnings call on Friday. “We’ll continue to lean into that growth very assertively.”

Minnetonka, Minn.-based UnitedHealth Group’s Optum segment, which includes its provider arm, its pharmacy benefit manager, and its data and technology arm, reported an operating margin of 6.6% in the quarter ended June 30, compared with 7.3% in the prior-year period. Leaders said the decline was within its provider arm, Optum Health.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Why doctors need education on FDA device approval process

knowledge

WSS

Elizabeth Holmes banned from government health programs

How a scoliosis diagnosis changed the life of one young dancer

Test for long Covid? Researchers find new clue in blood samples

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

J&J to buy cancer drug developer Ambrx Biopharma

Feng Zhang CRISPR delivery startup lays off quarter of staff

Wikipedia

comprehensive

hotspot

The cancer drug shortage isn’t new — and neither are the solutions

Feng Zhang CRISPR delivery startup lays off quarter of staff

Medical records are filled with copy

The tragedy of Johnson & Johnson’s Covid vaccine

Medicare proposal to cover medical devices draws a mixed reaction

Research misconduct: Proposed new rules face resistance

Medicare proposal to cover medical devices draws a mixed reaction

3 medical device trends to watch in 2024

Psychedelics group wrestles with new pharma identity

EU regulator recommends expanding Mounjaro approval to obesity

focus

EU regulator recommends expanding Mounjaro approval to obesity

AI generated plenty of interest at JPM but not a lot of trust

Readout Newsletter: Merck, J&J, and long Covid

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

Independent physicians launch a new lobbying group

Research misconduct: Proposed new rules face resistance

knowledge

knowledge

hotspot

hotspot